Key result
AVR with the St. Jude Trifecta bioprosthesis demonstrates excellent haemodynamics and 2.5% 30-day mortality.
Population
200 consecutive patients undergoing aortic valve replacement, mean age 71.2, mean EuroSCORE II 3.98%.
Design
Cohort
Follow-up
30-day
Authors
Loading...
Supports early Trifecta valve use based on low gradients and mortality; extends observational data but leaves durability and comparative efficacy open.
Observational (n=200)
No
The Trifecta aortic bioprosthesis demonstrates excellent early hemodynamic performance with low gradients and minimal aortic insufficiency.
Permanyer et al. (2013) conducted an observational in Aortic valve replacement (n=200). St. Jude Medical Trifecta aortic bioprosthesis was evaluated on Clinical and haemodynamic performance (including 30-day mortality). Aortic valve replacement with the St. Jude Medical Trifecta bioprosthesis demonstrated excellent haemodynamic performance and an early 30-day mortality of 2.5%.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: